EAJF Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EST
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.12
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€2.23M
Enterprise Value€0.23
Total Cash (Recent Filing)€791.61K
Total Debt (Recent Filing)€1.40K
Price to Earnings (P/E)―
Beta-4.21
Next Earnings
Jun 09, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,320,301,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)44.16
P/FCF Ratio-0.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces interest obligations and financial risk while preserving flexibility for research investment or partnership development. Compared with a highly leveraged biotech, ValiRx has less refinancing pressure and fewer fixed claims competing with capital needed to advance its pipeline.
Partnering-led Business ModelAn out-licensing model can let ValiRx monetize scientific assets without bearing the full cost of late-stage trials, regulatory approval, and commercialization. Successful partnering could provide milestone payments, royalties, and external validation while limiting direct commercial infrastructure needs.
Focused Therapeutic PipelineConcentration on oncology and women’s health gives the company a defined therapeutic focus rather than an undifferentiated research strategy. Advancing candidates through development creates multiple potential partnering opportunities, allowing portfolio progress to support longer-term strategic value.
Bears Say
Declining And Minimal RevenueRevenue remains far too small to support the current cost base and declined materially year over year. This indicates that the partnering and licensing model has not yet produced dependable commercial scale, leaving future progress heavily dependent on new transactions or development milestones.
Persistent Operating LossesRecurring operating and net losses show that the business has not reached economic self-sufficiency. Continued losses can consume resources required for pipeline advancement, reduce strategic flexibility, and make the company increasingly dependent on successful asset development, licensing, or external financing.
Structural Cash Burn And Shrinking EquityDeeply negative operating and free cash flow demonstrate that operations are not self-funding and require continuing access to capital or partner receipts. The simultaneous reduction in equity signals that accumulated losses are weakening the financial base available to support future development.
ValiRx plc News
EAJF FAQ
What was ValiRx PLC’s price range in the past 12 months?
ValiRx PLC lowest stock price was €0.01 and its highest was €0.12 in the past 12 months.
What is ValiRx PLC’s market cap?
ValiRx PLC’s market cap is €2.23M.
When is ValiRx PLC’s upcoming earnings report date?
ValiRx PLC’s upcoming earnings report date is Jun 09, 2027 which is in 270 days.
How were ValiRx PLC’s earnings last quarter?
ValiRx PLC released its earnings results on Jun 22, 2026. The company reported -€0.003 earnings per share for the quarter.
Is ValiRx PLC overvalued?
According to Wall Street analysts ValiRx PLC’s price is currently Overvalued.
Does ValiRx PLC pay dividends?
ValiRx PLC does not currently pay dividends.
What is ValiRx PLC’s EPS estimate?
ValiRx PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx PLC have?
ValiRx PLC has 1,320,301,000 shares outstanding.
What happened to ValiRx PLC’s price movement after its last earnings report?
ValiRx PLC reported an EPS of -€0.003 in its last earnings report. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of ValiRx PLC?
Currently, no hedge funds are holding shares in DE:EAJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ValiRx PLC
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.
Evgen Pharma
―
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―